Breakthrough Cerebrospinal Fluid Biomarker Revolutionizes Diagnostic Accuracy for Parkinson’s Disease and Lewy Body Dementia

Researchers discover that DOPA decarboxylase levels in spinal fluid can accurately identify Parkinson's and Lewy body dementia, reducing misdiagnosis risks.

By: AXL Media

Published: Mar 24, 2026, 8:55 AM EDT

Source: Information for this report was sourced from Vrije Universiteit Brussel

A Molecular Breakthrough in Neurodegenerative Diagnostics

A collaborative research effort led by the Vrije Universiteit Brussel and the Amsterdam UMC has uncovered a significant biological indicator for Parkinson’s disease and dementia with Lewy bodies. The study identifies DOPA decarboxylase, a protein essential for the synthesis of dopamine, as a primary marker that appears in elevated concentrations within the cerebrospinal fluid of affected individuals. Dr. Katharina Bolsewig and Prof. Charlotte Teunissen spearheaded the research, which suggests that this protein could serve as a definitive signature for diseases that have historically been difficult to pinpoint through traditional clinical observation.

The Clinical Challenge of Symptomatic Overlap

Diagnosing dementia with Lewy bodies is notoriously difficult due to the significant overlap in symptoms with other cognitive impairments, particularly Alzheimer’s disease. Professor Sebastiaan Engelborghs, who heads the Department of Neurology at UZ Brussel, notes that patients are frequently misdiagnosed under the current medical paradigm. This diagnostic uncertainty is not merely academic, as incorrect labeling can lead to the administration of treatments that are ineffective or potentially hazardous to the patient. The introduction of an objective molecular tool aims to mitigate these risks by providing clinicians with verifiable biological data at the earliest stages of cognitive decline.

Developing High Sensitivity Laboratory Protocols

To validate the presence of the biomarker, the consortium engineered two distinct, high sensitivity laboratory tests designed to measure DOPA decarboxylase levels with extreme precision. The experimental data revealed that patients within the target group exhibited protein concentrations up to two and a half times higher than those found in healthy control subjects. This stark statistical difference provides a robust foundation for a diagnostic test that can be reliably replicated in a clinical setting, moving away from the subjective nature of behavioral assessments and toward a standardized biochemical profile.